About: COVID-19 in Children: Clinical Approach and Management

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in Children: Clinical Approach and Management Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 in Children: Clinical Approach and Management
Creator	Lodha, Rakesh Kabra, S Sankar, Jhuma Dhochak, Nitin
Source	Medline; PMC
abstract	COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-risk contacts of a confirmed case. Clinical symptoms are similar to any acute respiratory viral infection with less pronounced nasal symptoms. Disease seems to be milder in children, but situation appears to be changing. Infants and young children had relatively more severe illness than older children. The case fatality rate is low in children. Diagnosis can be confirmed by Reverse transcriptase – Polymerase chain reaction (RT-PCR) on respiratory specimen (commonly nasopharyngeal and oropharyngeal swab). Rapid progress is being made to develop rapid diagnostic tests, which will help ramp up the capacity to test and also reduce the time to getting test results. Management is mainly supportive care. In severe pneumonia and critically ill children, trial of hydroxychloroquine or lopinavir/ritonavir should be considered. As per current policy, children with mild disease also need to be hospitalized; if this is not feasible, these children may be managed on ambulatory basis with strict home isolation. Pneumonia, severe disease and critical illness require admission and aggressive management for acute lung injury and shock and/or multiorgan dysfunction, if present. An early intubation is preferred over non-invasive ventilation or heated, humidified, high flow nasal cannula oxygen, as these may generate aerosols increasing the risk of infection in health care personnel. To prevent post discharge dissemination of infection, home isolation for 1–2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children.
has issue date	2020-04-27(xsd:dateTime)
bibo:doi	10.1007/s12098-020-03292-1
bibo:pmid	32338347
has license	no-cc
sha1sum (hex)	a41199515429c693683721453bf00e05144dd1c2
schema:url	https://doi.org/10.1007/s12098-020-03292-1
resource representing a document's title	COVID-19 in Children: Clinical Approach and Management
has PubMed Central identifier	PMC7183927
has PubMed identifier	32338347
schema:publication	Indian J Pediatr
resource representing a document's body	covid:a41199515429c693683721453bf00e05144dd1c2#body_text
is schema:about of	named entity 'heated' named entity 'shock' named entity 'chemotherapeutic agents' named entity 'symptoms' named entity 'respiratory' named entity 'Rapid' named entity 'specific' named entity 'Infants' named entity 'ambulatory' named entity 'aerosols' named entity 'Children' named entity 'POINT IN TIME' named entity 'CHEMOTHERAPEUTIC AGENTS' named entity 'SURFACES' named entity 'IS PREFERRED' named entity 'ISOLATION' named entity 'NEED' named entity 'POLICY' named entity 'HOME' named entity 'ACUTE RESPIRATORY ILLNESS' named entity 'FOR CHILDREN' named entity 'INCREASING' named entity 'PRESENT' named entity 'reduce' named entity 'supportive care' named entity 'lopinavir/ritonavir' named entity 'strict' named entity 'RT-PCR' named entity 'severe' named entity 'organ dysfunction' named entity 'aerosol' named entity 'signs and symptoms' named entity 'hydroxychloroquine' named entity 'Severe Pneumonia' named entity 'prone position' named entity 'antiviral agents' named entity 'hypoxemia' named entity 'SARS-CoV-2' named entity 'MoHFW' named entity 'SARS-CoV-2' named entity 'hypoglycemia' named entity 'convalescent plasma transfusion' named entity 'aspirate' named entity 'soap and water' named entity 'critically ill patients' named entity 'tonsils' named entity 'pharynx' named entity 'nebulisation' named entity 'transport medium' named entity 'Chest X-ray' named entity 'ICU' named entity 'supportive care' named entity 'lymphopenia' named entity 'Wuhan' named entity 'hand sanitizer' named entity 'thrombocytopenia' named entity 'breathlessness' named entity 'hemodynamic' named entity 'high-risk' named entity 'asymptomatic' named entity 'spike protein' named entity 'antivirals' named entity 'Remdesivir' named entity 'SARS-CoV-2' named entity 'refractory' named entity 'ACE2 receptor' named entity 'prodrug' named entity 'COVID' named entity 'ARDS' named entity 'blood culture' named entity 'SARS-CoV-2' named entity 'Clinical trial' named entity 'pediatric' named entity 'case fatality rate' named entity 'shortness of breath' named entity 'Modes of transmission' named entity 'C-reactive protein' named entity 'child died'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software